A. Raubitschek

发表

Potential artifact for the increase of tumor associated antigens in serum samples from patients injected with monoclonal antibodies.

J. Schlom, J. Carrasquillo, P. Ferroni, 1991, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

Potential for Artifacts in Monitoring for the Detection of Tumor Associated Antigens (TAG-72 and CEA) in Serum from Patients Undergoing MAb-based Diagnostic and Therapeutic Protocols

J. Schlom, J. Carrasquillo, P. Ferroni, 1990, The International journal of biological markers.

Imaging glioma extent with 131I-TM-601.

A. Mamelak, J. Fiveash, S. Shen, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Innovations that influence the pharmacology of monoclonal antibody guided tumor targeting.

S. Larson, P. Hand, J. Schlom, 1990, Cancer research.

Comparative biodistributions of yttrium- and indium-labeled monoclonal antibody B72.3 in athymic mice bearing human colon carcinoma xenografts.

S. Mirzadeh, M. Brechbiel, J. Schlom, 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Intracerebral CpG Immunotherapy with Carbon Nanotubes Abrogates Growth of Subcutaneous Melanomas in Mice

B. Badie, Leying Zhang, E. Manuel, 2012, Clinical Cancer Research.

Comparison of bone marrow dosimetry and toxic effect of high dose 131I-labeled monoclonal antibodies administered to man.

S. Larson, J. Schlom, J. Carrasquillo, 1989, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

Studies concerning the effect of external irradiation on localization of radiolabeled monoclonal antibody B72.3 to human colon carcinoma xenografts.

P. Hand, J. Schlom, A. Molinolo, 1989, International journal of radiation oncology, biology, physics.

Expression in COS cells of a mouse-human chimaeric B72.3 antibody.

J. Schlom, M. Bodmer, D. Colcher, 1987, Protein engineering.

Monoclonal antibodies and immobilized antibodies

C. A. White, R. Krauss, M. Melamed, 1987 .

EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY

Tina N. Davis, Forrest M Kievit, Atique U. Ahmed, 2013 .

Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3.

J. Schlom, M. Roselli, M. Bodmer, 1989, Cancer research.

Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma.

M. Gonda, B. Guthrie, A. Mamelak, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Continuous infusion chemotherapy as a radiation-enhancing agent for yttrium-90-radiolabeled monoclonal antibody therapy of a human tumor xenograft.

O. Gansow, D. Colcher, A. Raubitschek, 1994, Gynecologic oncology.

Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments.

J. Wong, A. Wu, D. Ikle, 2001, Bioconjugate chemistry.

Numerical selection of optimal tumor imaging agents with application to engineered antibodies.

L E Williams, A A Raubitschek, J. Wong, 2001, Cancer biotherapy & radiopharmaceuticals.

Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts.

L E Williams, J. Wong, A. Wu, 1996, Cancer research.

T. Waldmann, M. Brechbiel, J. Carrasquillo, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates.

J. Shively, A. Raubitschek, A. Raubitschek, 1994, Bioconjugate chemistry.

High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment.

S S Gambhir, M E Phelps, L E Williams, 2000, Proceedings of the National Academy of Sciences of the United States of America.

A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.

J. Doroshow, J. Wong, A. Wu, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.

J M Esteban, L E Williams, A A Raubitschek, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Intracerebral CpG Immunotherapy with Carbon Nanotubes Abrogates Growth of Subcutaneous Melanomas in Mice

B. Badie, Leying Zhang, E. Manuel, 2012, Clinical Cancer Research.

Mammalian expression and hollow fiber bioreactor production of recombinant anti-CEA diabody and minibody for clinical applications.

A A Raubitschek, A. Wu, J. Shively, 2001, Journal of immunological methods.